Tag
The RESOLVE trial demonstrates that 8 weeks of sofosbuvir-velpatasvir treatment is non-inferior to the standard 12-week regimen in treatment-naive, non-cirrhotic chronic hepatitis C patients, supporting shorter treatment duration without co
This study explores how patient language preference affects the offer and acceptance of hepatitis C screening in emergency departments, highlighting disparities and suggesting targeted approaches to improve screening among non-English speak
A 7-day perioperative sofosbuvir/velpatasvir prophylaxis in HCV-positive donor to HCV-negative recipient kidney transplants demonstrated sustained virologic response in over 92% of cases, with favorable 1-year graft survival and function.
Emergency departments serve as vital venues for hepatitis C virus screening, particularly for persons experiencing homelessness who exhibit higher HCV prevalence and face healthcare access barriers. Evidence supports nontargeted screening i
Long-term data from the BArT study and prospective observational trials demonstrate that direct-acting antivirals (DAAs) can achieve 100% viral clearance and durable hematologic responses in HCV-associated indolent lymphomas, potentially re
The DETECT Hep C trial demonstrates nontargeted HCV screening in emergency departments identifies more new infections than risk-based approaches, though linkage to care remains suboptimal, underscoring the need for innovative treatment mode
A study published in Pediatrics reveals low rates of hepatitis C treatment among children, highlighting significant racial disparities and access challenges.
